HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets.

Abstract
von Willebrand disease (VWD) type 2B is characterized by gain-of-function mutations in von Willebrand factor (VWF), enhancing its binding affinity for the platelet receptor glycoprotein (GP)Ibα. VWD type 2B patients display a bleeding tendency associated with loss of high-molecular-weight VWF multimers and variable thrombocytopenia. We recently demonstrated that a marked defect in agonist-induced activation of the small GTPase, Rap1, and integrin αIIbβ3 in VWD (p.V1316M) type 2B platelets also contributes to the bleeding tendency. Here, we investigated the molecular mechanisms underlying impaired platelet Rap1 signaling in this disease. Two distinct pathways contribute to Rap1 activation in platelets: rapid activation mediated by the calcium-sensing guanine nucleotide exchange factor CalDAG-GEF-I (CDGI) and sustained activation that is dependent on signaling by protein kinase C (PKC) and the adenosine 5'-diphosphate receptor P2Y12. To investigate which Rap1 signaling pathway is affected, we expressed VWF/p.V1316M by hydrodynamic gene transfer in wild-type and Caldaggef1-/- mice. Using αIIbβ3 integrin activation as a read-out, we demonstrate that platelet dysfunction in VWD (p.V1316M) type 2B affects PKC-mediated, but not CDGI-mediated, activation of Rap1. Consistently, we observed decreased PKC substrate phosphorylation and impaired granule release in stimulated VWD type 2B platelets. Interestingly, the defect in PKC signaling was caused by a significant increase in baseline PKC substrate phosphorylation in circulating VWD (p.V1316M) type 2B platelets, suggesting that the VWF-GPIbα interaction leads to preactivation and exhaustion of the PKC pathway. Consistent with PKC preactivation, VWD (p.V1316M) type 2B mice also exhibited marked shedding of platelet GPIbα. In summary, our studies identify altered PKC signaling as the underlying cause of platelet hypofunction in p.V1316M-associated VWD type 2B.
AuthorsCaterina Casari, David S Paul, Sophie Susen, Cécile Lavenu-Bombled, Annie Harroche, Raymond Piatt, Kathryn O Poe, Robert H Lee, Marijke Bryckaert, Olivier D Christophe, Peter J Lenting, Cécile V Denis, Wolfgang Bergmeier
JournalBlood advances (Blood Adv) Vol. 2 Issue 12 Pg. 1417-1428 (06 26 2018) ISSN: 2473-9537 [Electronic] United States
PMID29925524 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Copyright© 2018 by The American Society of Hematology.
Chemical References
  • Platelet Glycoprotein GPIb-IX Complex
  • von Willebrand Factor
  • Protein Kinase C
  • rap1 GTP-Binding Proteins
Topics
  • Animals
  • Blood Platelets (pathology)
  • Humans
  • Mice
  • Mutation, Missense
  • Platelet Glycoprotein GPIb-IX Complex (metabolism)
  • Protein Kinase C (metabolism)
  • Signal Transduction
  • rap1 GTP-Binding Proteins (metabolism)
  • von Willebrand Disease, Type 2 (blood, genetics)
  • von Willebrand Factor (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: